Drug News May 12, 2026
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
This article from Eli Lilly Press Releases covers: Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two...
Source: Eli Lilly Press Releases • Editorial summary by GLP-1 Price Guide
What This Means for You
This article from Eli Lilly Press Releases covers: Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two...
This article from Eli Lilly Press Releases covers: Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials.
Source: Eli Lilly Press Releases
Original source
Read the full article at Eli Lilly Press Releases